Psoriasis and vitiligo are 2 autoimmune conditions that can occur concurrently in patients. At present, no single systemic therapy has been identified to be effective in treating both the conditions.
Observations:
Recent advances in our understanding of the T helper (Th) 17 subset of Th cells suggests that interleukin (IL)-17 may play a key role in the pathogenesis of both vitiligo and psoriasis. We report a case of anatomically superimposed psoriatic plaques and vitiligo for which treatment with ixekizumab leads to resolution of psoriasis but did not improve the patient’s vitiligo.
Conclusion:
While IL-17 is highly effective in the treatment of psoriasis, it does not seem to be an effective treatment for vitiligo.
WeaverCTHattonRDManganPRHarringtonLE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821–852. doi:10.1146/annurev.immunol.25.022106.141557.
2.
SatoKSuematsuAOkamotoK. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673–2682. doi:10.1084/jem.20061775.
3.
LiJChenXLiuZYueQLiuH. Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technol Med Sci. 2007;27(3):330–332. doi:10.1007/s11596-007-0329-1.
4.
Vaknin-DembinskyABalashovKWeinerHL. IL-23 is increased in dendritic cells in multiple sclerosis, and downregulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol. 2006;176(12):7768–7774.
KruegerJGFretzinSSuárez-FariñasM. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145–154.e9. doi:10.1016/j.jaci.2012.04.024.
7.
GottliebABBlauveltAPrinzJC. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: results of the FEATURE trial. J Drugs Dermatol. 2016;15(10):1226–1234.
8.
LangleyRGLebwohlMKruegerGG. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371–1383. doi:10.1111/bjd.13469.
9.
BlauveltAGooderhamMIversenL. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017;77(5):855–862. doi:10.1016/j.jaad.2017.06.153.
10.
BassiounyDAShakerO. Role of interleukin-17 in the pathogenesis of vitiligo: role of IL-17 in the pathogenesis of vitiligo. Clin Exp Dermatol. 2011;36(3):292–297. doi:10.1111/j.1365-2230.2010.03972.x.
11.
BasakPYAdilogluAKCeyhanAMTasTAkkayaVB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol. 2009;60(2):256–260. doi:10.1016/j.jaad.2008.09.048.
12.
KhanRGuptaSSharmaA. Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-β) in patients with vitiligo. J Am Acad Dermatol. 2012;66(3):510–511. doi:10.1016/j.jaad.2011.07.018.
13.
ZhouLShiYLLiK. Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. Pigment Cell Melanoma Res. 2015;28(3):324–329. doi:10.1111/pcmr.12355.
14.
TembhreMKSharmaVKSharmaAChattopadhyayPGuptaS. T helper and regulatory T cell cytokine profile in active, stable, and narrow band ultraviolet B treated generalized vitiligo. Clinica Chimica Acta. 2013;424:27–32. doi:10.1016/j.cca.2013.05.005.
15.
KotobukiYTanemuraAYangL. Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell Melanoma Res. 2012;25(2):219–230. doi:10.1111/j.1755-148X.2011.00945.x.
16.
Méry-BossardLBagnyKChabyG. New-onset vitiligo and progression of preexisting vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol. 2017;31(1):181–186. doi:10.1111/jdv.13759.
17.
ZouJPreskyDHWuCYGublerU. Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits beta1 and beta2 and JAK kinases. J Biol Chem. 1997;272(9):6073–6077.
18.
ParhamCChiricaMTimansJ. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23 R. J Immunol. 2002;168(11):5699–5708.
19.
CaponFDi MeglioPSzaubJ. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122(2):201–206. doi:10.1007/s00439-007-0397-0.
20.
CargillMSchrodiSJChangM. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273–290.
21.
NairRPRuetherAStuartPE. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128(7):1653–1661. doi:10.1038/sj.jid.5701255.
22.
HaHLWangHPisitkunP. IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. Proc Natl Acad Sci U S A. 2014;111(33):E3422–E3431. doi:10.1073/pnas.1400513111.
23.
LeonardiCMathesonRZachariaeC. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–1199. doi:10.1056/NEJMoa1109997.
24.
WingKSakaguchiS. Regulatory T cells exert checks and balances on self-tolerance and autoimmunity. Nat Immunol. 2010;11(1):7–13. doi:10.1038/ni.1818.
25.
SugiyamaHGyulaiRToichiE. Dysfunctional blood and target tissue CD4 + CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol. 2005;174(1):164–173. doi:10.4049/jimmunol.174.1.164.
26.
BovenschenHJvan de KerkhofPCvan ErpPEWoestenenkRJoostenIKoenenHJ. Foxp3 + regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol. 2011;131(9):1853–1860. doi:10.1038/jid.2011.139.
27.
RashighiMAgarwalPRichmondJM. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23-223ra23. doi:10.1126/scitranslmed.3007811.
28.
PasseronTOrtonneJP. Vitiligo and other disorders of hypopigmentation. In: BologniaJSchafferJV, eds. Dermatology. 4th ed. Philadelphia, PA: Elsevier; 2018:1087–1114.
NadaHREl SharkawyDAElmasryMFRashedLAMamdouhS. Expression of Janus Kinase 1 in vitiligo and psoriasis before and after narrow band B: a case-control study. Arch Dermatol Res. 2018;310(1):39–46. doi:10.1007/s00403-017-1792-6.
31.
CraiglowBGKingBA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatology. 2015;151(10):1110–1112. doi:10.1001/jamadermatol.2015.1520.
32.
RothsteinBJoshipuraDSaraiyaA. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054–1060.e1. doi:10.1016/j.jaad.2017.02.049.
33.
WongRLWinslowCCooperK. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today. 1993Feb;14(2):69–74.
34.
WhittonMEPinartMBatchelorJ. Interventions for vitiligo. Cochrane Database Syst Rev. 2015;(2):CD003263. doi:10.1002/14651858.CD003263.pub5
35.
GuptaAK.Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses: a clinical and immunopathologic analysis. Arch Dermatol. 1990;126(3):339–350. doi:10.1001/archderm.1990.01670270071012.
